Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...
Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...
Neuphoria Therapeutics Inc. (NASDAQ:NEUP) stock soared over 20% following the announcement that the company will receive a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback